Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

HERV-W envelope protein inhibits oligodendroglial precursor cell differentiation.
Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.
Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis.
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.
The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
Modulation of Sox10, HIF-1α, Survivin, and YAP by Minocycline in the Treatment of Neurodevelopmental Handicaps following Hypoxic Insult.
The environment and disease: association or causation?
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
MRI in multiple sclerosis: a review of the current literature.
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Medical marijuana: clearing away the smoke.
In vivo evidence of glutamate toxicity in multiple sclerosis.
Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis.
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU
In vitro Biological Characterization of IFN-β-1a major Glycoforms.
Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study.
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.

Pages